A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases

BACKGROUND: Cabozantinib is an oral MET/VEGFR2 inhibitor. A recent phase II study of cabozantinib (100mg daily) demonstrated improved bone scans in subjects with metastatic castration-resistant prostate cancer (mCRPC), but adverse events (AEs) caused frequent dose reductions. This study was designed...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Lee, Richard J., Saylor, Philip J., Michaelson, M. Dror, Rothenberg, S. Michael, Smas, Malgorzata E., Miyamoto, David T., Gurski, Carol A., Xie, Wanling, Maheswaran, Shyamala, Haber, Daniel A., Goldin, Jonathan G., Smith, Matthew R.
Format: Artigo
Idioma:Inglês
Publicat: 2013
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3684567/
https://ncbi.nlm.nih.gov/pubmed/23553848
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-13-0319
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars